4D Pharma shares have rocketed and I’m tempted to buy now

4D Pharma shares leapt last week and the momentum is continuing. Given its potential game-changer drugs, it’s a stock Andy Ross wants to add to his portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investors who bought 4D Pharma (LSE: DDDD) shares have had a torrid 12 months. The share price of the biotechnology company has fallen by 30% over the last year. But they were down further until late last week (and this week so far) as the shares have recently leapt. It’s not immediately clear why the share price has risen so rapidly. What’s clear though is that 4D Pharma has a lot of potential and it’s for that reason that I’m tempted to buy the shares now.

Why I’m tempted to buy despite the risks 

Given that many investors won’t have heard of 4D Pharma, I’ll start by explaining what it does. It focuses on developing Live Biotherapeutic Products (LBPs), which are drugs derived from the human microbiome. It has developed its research to build MicroRx, which is a discovery platform that’s able to select those bacteria that have a therapeutic effect in specific diseases, including cancer.

The company has 10 main programmes in development. These include two drugs that have reached phase II clinical trials and are progressing relatively well through the drug testing process. It also has a research collaboration with MSD, a trade name of Merck to discover and develop Live Biotherapeutics for vaccines.

This close partnership with a major pharmaceuticals firm could open the door to further collaboration in future, I think, and Merck could even buy the therapies as they progress through the drugs approvals process. I believe this would be a good outcome for shareholders as it would raise cash and move 4D pharma towards being profitable. 

For now though, the company remains loss-making. Losses in 2020 were around £26m. Yet 4D Pharma has cash and cash deposits that cover about a year’s worth of research and development costs. In 2021 the biotech firm raised approximately $24.03m (£17.29m) in a private placement. It has also secured a credit facility for up to $30m with Oxford Finance SARL. That’s all good news, but despite this extra money, it could still need to once again call on investors for even more, which would have the effect of diluting any holdings. I feel that raising longer-term debt would usually be preferable from a shareholder perspective.

The bottom line

Given UK investors have no other share like 4D Pharma to buy, I think that if evidence builds around the value of the microbiome in healthcare, 4D Pharma’s shares should do well. Investing in the stock is clearly not about today’s fundamentals. The investment case is all about how 4D Pharma is a world leader in an exciting new area of healthcare innovation and about its future potential. 

Of course, it’s possible 4D Pharma shares could be worth nothing. It’s a speculative, high-risk company to invest in. There are no two ways about that to my mind. But most rewards involve calculated risks. So, I would put aside just a small part of my overall cash to add 4D Pharma shares to my portfolio, given their huge potential. If just some of what’s in the pipeline works as expected, it could be transformational. When — or if — the potential of the microbiome in healthcare is proven, the 4D Pharma share price could rise very quickly. It may be a roller coaster ride up to that point though, but it’s one I’m prepared for. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Andy Ross owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Photo of a man going through financial problems
Investing Articles

Down 16% in a month! Can this FTSE 100 stock recover in April?

Grabbing low-priced shares with long-term growth potential is an investor's dream. I think this FTSE 100 share may be an…

Read more »

Buffett at the BRK AGM
Investing Articles

Warren Buffett is an investing genius. But what might he buy if he were British?

I'm wondering what investing legend Warren Buffett would pick for his portfolio if he had been born on this side…

Read more »

The words "what's your plan for retirement" written on chalkboard on pavement somewhere in London
Retirement Articles

If I was approaching retirement, I’d buy these 3 dividend stocks for passive income

Edward Sheldon highlights three UK dividend stocks he’d snap up if he was getting his investment portfolio ready for retirement.

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Market Movers

Why the stock market is down 1.4% today

Jon Smith runs through several reasons for the fall in the stock market today, with examples of stock that are…

Read more »

Investing Articles

At a 10-year low, here’s what the charts say for this FTSE 100 stock!

Legal troubles, compliance issues, and dismal sales have sent this FTSE 100 stock tumbling, but could a share price recovery…

Read more »

Bronze bull and bear figurines
Investing Articles

1 dividend superstar I’d buy over Lloyds shares right now

I sold my Lloyds shares recently and have used some of the proceeds to buy more of this high-yielding dividend…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£20,000 in savings? Here’s how I’d try to turn that into a £43,960 annual passive income!

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends can generate significant passive income over time.

Read more »

Sun setting over a traditional British neighbourhood.
Investing Articles

Could I make shedloads of dividend income from 8,025 Kingfisher shares?

Some shares are better than others when it comes to earning dividend income. So how does this FTSE 100 do-it-yourself…

Read more »